000 07595cam a2200817 i 4500
001 ocn927362841
003 OCoLC
005 20200827105145.0
006 m o d f
007 cr un|||||||||
008 151202s2015 dcua obt 100 0 eng
040 _aNLM
_beng
_erda
_epn
_cNLM
_dCUS
_dMMU
_dN$T
_dYDXCP
_dEBLCP
_dUAB
_dBUF
_dOCLCF
_dOCLCO
_dOCLCQ
_dEZ9
_dOCLCA
_dOCLCQ
_dOCLCO
_dWYU
_dNLM
_dOCLCO
_dOCLCA
_dOCLCQ
_dOCLCO
016 7 _a101673538
_2DNLM
020 _a9780309373241
020 _a0309373247
020 _z9780309373234
_q(paperback)
020 _z0309373239
_q(paperback)
029 0 _aNLM
_b101673538
029 1 _aDEBBG
_bBV044026931
035 _a(OCoLC)927362841
042 _apcc
043 _an-us---
050 4 _aRM301.25
_b.N67 2015
060 0 0 _a2016 C-538
060 1 0 _aQV 76.5
072 7 _aMED
_x071000
_2bisacsh
082 0 4 _a615.19
_223
049 _aMAIN
111 2 _aFinancial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders (Workshop)
_d(2015 :
_cWashington, D.C.),
_jauthor.
_0http://id.loc.gov/authorities/names/no2015147304
245 1 0 _aFinancial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders :
_bworkshop summary /
_cSheena M. Posey Norris, Evelyn Strauss, Christopher DeFeo, and Clare Stroud, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
264 1 _aWashington, D.C. :
_bNational Academies Press,
_c2015.
300 _a1 online resource (1 PDF file (xiv, 114 pages)) :
_billustrations
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aTitle from PDF title page.
504 _aIncludes bibliographical references.
520 3 _aThe Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders, in collaboration with the IOM Forum on Drug Discovery, Development, and Translation, convened a workshop on January 20-21, 2015, to explore policy changes that might increase private sector investment in research and development innovation that fills unmet medical needs for central nervous system (CNS) disorders. Workshop participants strategized about how to incentivize companies to fortify their CNS drug development programs, shrinking obstacles that currently deter ventures. Representatives from academia, government agencies, patient groups, and industry gathered to share information and viewpoints, and to brainstorm about budget-neutral policy changes that could help widen the pipeline toward drugs that address unmet needs for CNS disorders. This report summarizes the presentations and discussion of the workshop.
536 _aThis project was supported by contracts between the National Academy of Sciences and AbbVie; the Alzheimer's Association; American Diabetes Association; American Society of Microbiology; Amgen Inc. (Contract No. GHCCOPS-CSARF-63987); Association of American Medical Colleges; AstraZeneca; Baxter BioScience; Brain Canada Foundation; Burroughs Wellcome Fund (Contract No. 1015149); Critical Path Institute; the Department of Health and Human Services' Food and Drug Administration (Contract No. 1R13FD005154-01) and National Institutes of Health (NIH, Contract Nos. HHSN26300026 and HHSN263201200074I, Task Order HHSN26300023 [Under Master Base #DHHS-10001292]) through the National Cancer Institute, National Center for Advancing Translational Sciences, National Center for Complementary and Integrative Health, National Eye Institute, National Institute of Allergy and Infectious Disease, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, and NIH Blueprint for Neuroscience Research; Department of Veterans Affairs (VA240-14-C-0057); Doris Duke Charitable Foundation (Contract No. 2015103); Eli Lilly and Company; FasterCures; Foundation for the National Institutes of Health; Friends of Cancer Research; the Gatsby Charitable Foundation; GlaxoSmithKline, Inc. (Contract No. 005319); Johnson & Johnson Pharmaceutical Research and Development, LLC; Lundbeck Research USA; Merck & Co., Inc. (Contract No. CMO-141224-000649); The Michael J. Fox Foundation for Parkinson's Research; the National Multiple Sclerosis Society; the National Science Foundation (Contract No. BCS-1064270); New England Journal of Medicine; One Mind for Research; Orion Bionetworks; Pfizer Inc.; Pharmaceutical Product Development, LLC; Sanofi; the Society for Neuroscience; Takeda Pharmaceutical Company Limited (Contract No. 53108); and Wellcome Trust. The views presented in this publication do not necessarily reflect the views of the organizations or agencies that provided support for this project.
588 0 _aVersion viewed December 21, 2015.
505 0 _aIntroduction and overview -- Improving market protection -- Strengthening the regulatory pathway -- Patient benefit and engagement.
590 _aeBooks on EBSCOhost
_bEBSCO eBook Subscription Academic Collection - Worldwide
650 0 _aDrug development
_xEconomic aspects
_vCongresses.
650 0 _aCentral nervous system
_xDiseases
_xEffect of drugs on
_vCongresses.
650 0 _aPharmaceutical industry
_xEconomic aspects
_vCongresses.
650 0 _aPublic-private sector cooperation
_vCongresses.
650 1 2 _aCentral Nervous System Agents
_xeconomics.
_0https://id.nlm.nih.gov/mesh/D002491Q000191
650 2 2 _aDrug Discovery
_xeconomics.
_0https://id.nlm.nih.gov/mesh/D055808Q000191
650 2 2 _aFinancial Support.
_0https://id.nlm.nih.gov/mesh/D005378
650 2 2 _aNervous System Diseases
_xdrug therapy.
_0https://id.nlm.nih.gov/mesh/D009422Q000188
650 2 2 _aNervous System Diseases
_xeconomics.
_0https://id.nlm.nih.gov/mesh/D009422Q000191
650 2 2 _aPrivate Sector
_xeconomics.
_0https://id.nlm.nih.gov/mesh/D017149Q000191
650 7 _aMEDICAL
_xPharmacology.
_2bisacsh
650 7 _aPharmaceutical industry
_xEconomic aspects.
_2fast
_0(OCoLC)fst01060138
650 7 _aPublic-private sector cooperation.
_2fast
_0(OCoLC)fst01083445
655 2 _aCongress.
_0https://id.nlm.nih.gov/mesh/D016423
655 4 _aElectronic books.
655 7 _aConference papers and proceedings.
_2fast
_0(OCoLC)fst01423772
700 1 _aNorris, Sheena M. Posey,
_eauthor.
700 1 _aStrauss, Evelyn,
_eauthor.
700 1 _aDe Feo, Christopher Joseph,
_eauthor.
700 1 _aStroud, Clare,
_eauthor.
710 2 _aInstitute of Medicine (U.S.).
_bForum on Neuroscience and Nervous System Disorders,
_esponsoring body.
_0http://id.loc.gov/authorities/names/no2008032406
710 2 _aInstitute of Medicine (U.S.).
_bForum on Drug Discovery, Development, and Translation,
_esponsoring body.
_0http://id.loc.gov/authorities/names/no2007051854
776 0 8 _iPrint version:
_tFinancial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders.
_dWashington, D.C. : National Academies Press, [2015]
_z0309373239
_w(OCoLC)921241584
856 4 0 _uhttps://libproxy.firstcity.edu.my:8443/login?url=http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1029476
938 _aEBL - Ebook Library
_bEBLB
_nEBL4393789
938 _aEBSCOhost
_bEBSC
_n1029476
938 _aYBP Library Services
_bYANK
_n12724313
994 _a92
_bMYFCU
999 _c47330
_d47330